Refractory thrombotic thrombocytopenic purpura associated with oral contraceptives and factor V Leiden: A case report

Cases Journal

Volumn 2, Issue 5, 2009, Pages

  Stylianou, Kostas ^a   Tsirakis, George ^a   Mantadakis, Elpis ^a   Xylouri, Irini ^a   Foudoulakis, Andreas ^a   Vardaki, Eleftheria ^a   Katsipi, Irene ^a   Daphnis, Eugene ^a   Samonis, George ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CORTICOSTEROID; ETHINYLESTRADIOL PLUS GESTODENE; HARMONETTE; LACTATE DEHYDROGENASE; PREDNISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; ATTRIBUTABLE RISK; CASE REPORT; CAUCASIAN; CONVALESCENCE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG MEGADOSE; DYSARTHRIA; DYSMENORRHEA; FEMALE; HEMATURIA; HEMOLYTIC ANEMIA; HUMAN; LETHARGY; PHYSICAL EXAMINATION; PLASMAPHERESIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS;

EID: 77953421049     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.1186/1757-1626-2-6611     Document Type: Article

References (16)

1. George JN, Kremer Hovinga JA, Terrell DR, Vesely SK, Lammle B: The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection. European J Haematol 2008, 80:277-286.
2. Sadler JE: VonWillebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008, 112:11-18.
3. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, Bevan D, Mackie I, Machin S: Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008, 142:819-826.
4. Krieg S, Studt JD, Sulzer I, Lammle B, Hovinga JA: Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? Thromb Haemost 2005, 94:1186-1189.
5. Hauglustaine D, Van Damme B, Vanrenterghem Y, Michielsen P: Recurrent hemolytic uremic syndrome during oral contraception. Clin Nephrol 1981, 15:148-153.
6. Hauglustaine D, Vanrenterghem Y, Michielsen OP, van Damme B: Oestrogen containing oral contraceptives, decreased prostacyclin production, and haemolytic uraemic syndrome. Lancet 1981, 1:328-329.
7. Holdrinet RS, de Pauw BE, Haanen C: Hormonal dependent thrombotic thrombocytopenic purpura (TTP). Scand J Haematol 1983, 30:250-256.
8. Vesconi S, Langer M, Rossi E, Mondonico P, Cambiaghi G, Donati MB: Thrombotic thrombocytopenic purpura during oral contraceptive treatment. Thromb Haemost 1979, 40:563-564.
9. Montes A, Powles TJ, O'Brien ME, Ashley SE, Luckit J, Treleaven J: A toxic interaction between mitomycin C and tamoxifen during the haemolytic uraemic syndrome. Eur J Cancer 1993, 29A:1854-1857.
10. Au WY, Chan KW, Lam CC, Young K: A post-menopausal woman with anuria and uterus bulk: the spectrum of estrogen-induced TTP/HUS. Am J Hematol 2002, 71:59-60.
11. Liang R, Wong RW, Cheng IK: Thrombotic thrombocytopenic purpura and 17 beta-estradiol transdermal skin patch. Am J Hematol 1996, 52:334-335.
12. Shamseddine A, Chehal A, Usta I, Salem Z, El-Saghir N, Taher A: Thrombotic thrombocytopenic purpura and pregnancy: report of four cases and literature review. J Clin Apher 2004, 19:5-10.
13. Fraser JL, Millenson M, Malynn ER, Uhl L, Kruskall MS: Possible association between the Norplant contraceptive system and thrombotic thrombocytopenic purpura. Obstet Gynecol 1996, 87:860-863.
14. Raife TJ, Lentz SR, Atkinson BS, Vesely SK, Hessner MJ: Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002, 99:437-442.
15. Allford SL, Hunt BJ, Rose P, Machin SJon behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology: Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anemias. Br J Heamatol 2003, 120:556-573.
16. Wada H, Mori Y, Shimura M, Hiyoyama K, Ioka M, Nakasaki T, Nishikawa M, Nakano M, Kumeda K, Kaneko T, Nakamura S, Shiku H: Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1998, 58:189-194.